Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
78.59
-1.35 (-1.69%)
At close: Oct 16, 2026, 4:00 PM EDT
78.54
-0.05 (-0.06%)
After-hours: Oct 16, 2026, 7:30 PM EDT
Kiniksa Pharmaceuticals International, Employees
Kiniksa Pharmaceuticals International, had 366 employees as of December 31, 2025. The number of employees increased by 51 or 16.19% compared to the previous year. That makes Kiniksa Pharmaceuticals International, the 22,420th largest employer in the world and 2,926th in the United States.
Employees
366
Change (1Y)
51
Growth (1Y)
16.19%
Revenue / Employee
$2,297,399
Profits / Employee
$220,377
Market Cap
6.13B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 366 | 51 | 16.19% | 366 | 0 |
| Dec 31, 2024 | 315 | 18 | 6.06% | 315 | 0 |
| Dec 31, 2023 | 297 | 77 | 35.00% | 297 | 0 |
| Dec 31, 2022 | 220 | 5 | 2.33% | 220 | 0 |
| Dec 31, 2021 | 215 | 47 | 27.98% | 215 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Dr. Reddy's Laboratories | 27,527 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
| Neurocrine Biosciences | 2,000 |
| Lantheus Holdings | 1,193 |
| Indivior Pharmaceuticals | 838 |
KNSA News
- 5 weeks ago - Kiniksa Pharmaceuticals International, Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 6 weeks ago - Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Kiniksa Pharmaceuticals International, Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 2 months ago - Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 2 months ago - Kiniksa price target raised to $90 from $75 at Goldman Sachs - TheFly
- 2 months ago - Kiniksa price target raised to $99 from $72 at Wedbush - TheFly
- 2 months ago - Kiniksa price target raised to $107 from $72 at JPMorgan - TheFly
- 2 months ago - Kiniksa price target raised to $98 from $64 at Canaccord - TheFly